Triazine compounds as P13 kinase and MTOR inhibitors

US8748421B2 · kind B2 · utility

Assignee

• Wyeth, LLC · US

Inventors

• Aranapakam Mudumbai Venkatesan · New York, US
• Zecheng Chen · New City, US
• Christoph Martin Dehnhardt · New York, US
• Osvaldo Dos Santos · New York, US
• Efren Guillermo Delos Santos · Nanuet, US
• Arie Zask · New York, US
• Jeroen Cunera Verheijen · Highland Mills, US
• Joshua A. Kaplan · Foster City, US
• David Richard · Monroe, US
• Semiramis Ayral-Kaloustian · Tarrytown, US
• Tarek Suhayl Mansour · New City, US
• Ariamala Gopalsamy · Lexington, US
• Kevin Joseph Curran · Nyack, US
• Mengxiao Shi · Eastchester, US

Key dates

• Filing date: Jul 25, 2013
• Grant date: Jun 10, 2014
• Expiry date: Jul 25, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D498/08
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds of formula I and R2, R4, and R6-9 are defined herein, and pharmaceutically acceptable salts and esters thereof. These compounds inhibit PI3 kinase and mTOR, and may be used to treat diseases mediated by PI3 kinase and mTOR, such as a variety of cancers. Methods for making and using the compounds of this invention are disclosed. Various compositions containing the compounds of this invention are also disclosed.